Latest CanVECTOR News
 

Annual incidence of

2/1000

population per year

Cost of VTE: at least

$600m

CAD a year

VTE recurrence

5-10%

per year

Chronic thromboembolic pulmonary hypertension 

3-4%

after PE

Pulmonary Embolism
leads to the hospitalization
or death of over

30,000

Canadians every year

VTE leads to significant

long-term
costs

in the form of chronic complications of VTE

Post-thrombotic syndrome

20-40%

after DVT

Adverse effects and

burden of anticoagulant therapy

Upcoming Events

Evidence Pearls on VTE

Evidence Pearls on VTE RSS Feed
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.
Nov 17, 2017
Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
Nov 17, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 17, 2017
Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years.
Nov 17, 2017
CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study.
Nov 17, 2017
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.
Nov 16, 2017
Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
Nov 16, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 16, 2017
Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
Nov 15, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 15, 2017
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Nov 15, 2017
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.
Nov 15, 2017
Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
Nov 14, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 14, 2017
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Nov 14, 2017
Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
Nov 13, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 13, 2017
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Nov 13, 2017
The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up.
Nov 12, 2017
Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Nov 12, 2017
1 2 3 4 5 6 7 8 9 10 11 12 Next

Twitter